Intervention Protocol

Oral versus intravenous fluoropyrimidines for metastatic colorectal cancer.

  1. Andrew Strickland1,*,
  2. Peter Harper2,
  3. Christos Karapetis3,
  4. Christopher B Steer4,
  5. Desmond Yip5

Editorial Group: Cochrane Colorectal Cancer Group

Published Online: 23 OCT 2000

DOI: 10.1002/14651858.CD002889


How to Cite

Strickland A, Harper P, Karapetis C, Steer CB, Yip D. Oral versus intravenous fluoropyrimidines for metastatic colorectal cancer. (Protocol). Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD002889. DOI: 10.1002/14651858.CD002889.

Author Information

  1. 1

    Guy's Hospital, Medical Oncology, London, UK

  2. 2

    South East London Cancer Research Network, Guy's Hospital, Medical Oncology, London, UK

  3. 3

    Flinders Medical Centre, Department of Oncology, Bedford Park, SA, Australia

  4. 4

    Border Medical Oncology, Victoria, Australia

  5. 5

    The Canberra Hospital, Medical Oncology Unit, Garran, ACT, Australia

*Andrew Strickland, Medical Oncology, Guy's Hospital, St Thomas St, London, SE1 9RT, UK. andrew.strickland@kcl.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 23 OCT 2000

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Our primary objective is to conduct a systematic review of the randomised trials comparing intravenous 5-fluorouracil with any oral fluoropyrimidine to assess the effect of chemotherapy on overall survival in patients with colo-rectal cancer. Our secondary objective will be to assess the relative response rates, toxicities and effects on quality of life of these two treatments.